DBV TECHNOLOGIES
LIVE

Serial Number

79364819

Owner

DBV TECHNOLOGIES

Attorney

Jennifer Sheehan Anderson

Filing Date

Sep 19, 2022

Add to watchlist:

No watchlists yet
View on USPTO

DBV TECHNOLOGIES Trademark

Serial Number: 79364819 • Registration: 7390033

DBV TECHNOLOGIES is a trademark filed by DBV TECHNOLOGIES on September 19, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

DBV TECHNOLOGIES (42 trademarks)

177-181 avenue Pierre Brossolette
Montrouge 92120 , FR

Entity Type: 99

Trademark Details

Filing Date

September 19, 2022

Registration Date

May 21, 2024

Published for Opposition

March 5, 2024

Goods & Services

Educational services for consumers and professionals in the field of immunotherapy, namely, organizing classes, seminars, programs, conferences, congresses, workshops in the field of immunotherapy; organizing and providing exhibitions for online educational purposes featuring interactive presentations and exhibitions in the field of immunotherapy; publishing periodicals, books, and guides in the field of immunotherapy; database publishing services, namely publishing of periodical journals containing printed databases in tabular form in the field of immunotherapy; providing information with respect to education in the field of immunotherapy via an online website

Medicated adhesive devices in the nature of epicutaneous patches enabling the cutaneous or epicutaneous administration of pharmaceutical or medicated substances in dry form for humans and animals for the treatment and prevention of allergies, autoimmune, inflammatory and infectious diseases; epicutaneous patches containing powdered preparations for medical use for the treatment and prevention of allergies, autoimmune, inflammatory and infectious diseases; medicated occlusion patches in the nature of epicutaneous patches enabling the absorption of powdered medicated substances through the skin for the treatment and prevention of allergies, autoimmune, inflammatory and infectious diseases

Medical services using desensitization methods on the principle of immunotherapy; medical treatment and prevention of allergies, inflammatory, autoimmune and infectious diseases through the administration of allergens, antigens using patches affixed to the patients' unbroken skin, thus avoiding the transfer of allergens into the blood; medical treatment and prevention of allergies, inflammatory, autoimmune and infectious diseases using epicutaneous methods of desensitization via immunotherapy; epicutaneous medical treatments and prevention of allergies, inflammatory, autoimmune and infectious diseases without prior preparation of the skin other than a simple rapid cleaning in order to leave the cell structure of the skin intact; medical consultancy in the field of desensitization to allergies with respect to desensitization to combat allergies

Medical apparatus, instruments and devices, namely, epicutaneous patches sold without medication for the cutaneous or epicutaneous administration of medicated or cosmetic substances in dry form for humans or animals; occlusion patch dispensers for medical use; medical instruments using the electrostatic properties of biocompatible media, namely, epicutaneous patches sold without medication

Medical and scientific research in the field of immunotherapy, namely, developing scientific methods for epicutaneous immunotherapy, to try to treat and prevent autoimmune, infectious and inflammatory diseases without prior preparation of the skin other than a simple rapid cleaning in order to leave the cell structure of the skin intact; scientific research in the field of allergy treatment and care; scientific research in the field of allergy treatment for the repeated application of treatments to patients' skin without prior preparation of the skin other than a simple rapid cleaning in order to leave the cell structure of the skin intact and thus avoid the passage of allergens into the blood; allergenic drug discovery services; medical and scientific research services, namely, developing methods for treating allergies via contact between allergens and skin immune cells; medical and scientific research services, namely, developing methods for the treatment and prevention of allergies, autoimmune, infectious and inflammatory diseases by applying patches to patients' unbroken skin without prior preparation of the skin other than a simple rapid cleaning in order to leave the cell structure of the skin intact

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 30, 2024 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 9, 2024 FICS
FINAL DISPOSITION PROCESSED
Nov 9, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 21, 2024 FICR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jul 13, 2024 ADCH
NEW REPRESENTATIVE AT IB RECEIVED
Jun 15, 2024 NREP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 21, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
May 21, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 5, 2024 NPUB
PUBLISHED FOR OPPOSITION
Mar 5, 2024 PUBO
NOTIFICATION PROCESSED BY IB
Mar 4, 2024 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 14, 2024 OPNS
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 14, 2024 NPUB
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 14, 2024 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 14, 2024 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 26, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 24, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 24, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 24, 2024 TROA
REFUSAL PROCESSED BY IB
Aug 29, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 9, 2023 RFCS
REFUSAL PROCESSED BY MPU
Aug 9, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 5, 2023 RFCR
NON-FINAL ACTION WRITTEN
Jul 4, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 29, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 21, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 17, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 9, 2023 REPR